NCT06568198 Modulation Effect of tACS on Chronic Low Back Pain
| NCT ID | NCT06568198 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Massachusetts General Hospital |
| Condition | Chronic Low-back Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2025-08-25 |
| Primary Completion | 2028-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 80 participants in total. It began in 2025-08-25 with a primary completion date of 2028-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Investigating the modulation effect of tACS
Eligibility Criteria
Inclusion Criteria: 1. Volunteers 18-60 years of age 2. Meet the Classification Criteria of the chronic LBP (having low back pain for more than 6 months) 3. At least 4/10 clinical pain on the 0-10 LBP NRS 4. At least a 10th grade English-reading level; English can be a second language provided that the patients understand all questions used in the assessment measures 5. Meeting the MRI / MEG / EEG screening criteria Exclusion Criteria: 1. Specific causes of back pain (eg, cancer, fractures, spinal stenosis, infections) 2. Complicated back problems (eg, prior back surgery, medicolegal issues) 3. The intent to undergo surgery during the time of involvement in the study 4. History of cardiac, respiratory, or nervous system disease that, in the investigator's judgment, precludes participation in the study because of a heightened potential for adverse outcome (for example: asthma or claustrophobia) 5. Presence of any contraindications to MRI scanning (for example: cardiac pacemaker, metal implants, claustrophobia, pregnancy, cannot lie still in fMRI scanner) 6. Concomitant autoimmune, chronic, inflammatory, neoplastic, and psychiatric diseases 7. Pregnant or lactating 8. Conditions making study participation difficult (e.g., paralysis, psychoses, or other severe psychological problems as per the judgment of a study investigator during Session 1) 9. Active substance abuse disorders (based on subject self-report and drug test) 10. Regular use of pain medication such as opioids, nonopioid analgesics, coanalgesics, corticosteroids, or immunomodulatory agents 11. Any medical conditions, such as peripheral neuropathy, that could affect the results of QST 12. Current use of psychotropic medication
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06568198 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Chronic Low-back Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06568198 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06568198 currently recruiting?
Yes, NCT06568198 is actively recruiting participants. Contact the research team at jkong2@mgh.harvard.edu for enrollment information.
Where is the NCT06568198 trial being conducted?
This trial is being conducted at Charlestown, United States.
Who is sponsoring the NCT06568198 clinical trial?
NCT06568198 is sponsored by Massachusetts General Hospital. The trial plans to enroll 80 participants.